Literature DB >> 2190404

Use of intravesical bacillus Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder: an overview.

J A Witjes1, A P vd Meijden, F M Debruyne.   

Abstract

Since 1976 superficial bladder cancer is treated with intravesical instillations of Bacillus Calmette-Guérin (BCG). The results with BCG are superior to other intravesical chemotherapeutics, both in superficial tumors and carcinoma in situ. BCG probably acts as a nonspecific potentiator of the immune system. Comparative studies have to give information about the effectiveness and side effects of the different strains of BCG, and about the best clinical schedule. Toxicity is mild in 95% of the cases. Severe side effects and antituberculous drugs are discussed.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2190404     DOI： 10.1159/000281694

Source DB:  PubMed          Journal:  Urol Int        ISSN： 0042-1138            Impact factor:   2.089


  8 in total

1.  Rapid identification of mycobacteria and drug-resistant Mycobacterium tuberculosis by use of a single multiplex PCR and DNA sequencing.

Authors:  Ailyn C Pérez-Osorio; David S Boyle; Zachary K Ingham; Alla Ostash; Romesh K Gautom; Craig Colombel; Yolanda Houze; Brandon T Leader
Journal:  J Clin Microbiol       Date:  2011-12-07       Impact factor: 5.948

2.  BCG vaccine in urinary bladder cancer.

Authors:  S A Brosman
Journal:  West J Med       Date:  1991-12

Review 3.  Intravesical drug delivery. Pharmacokinetic and clinical considerations.

Authors:  M S Highley; A T van Oosterom; R A Maes; E A De Bruijn
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

4.  Tissue disposition and plasma concentrations of idarubicin after intravesical therapy in patients with bladder tumors.

Authors:  K Mross; K Hamm; W Schultze-Seemann; K Burk; D K Hossfeld
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Granulomatous hepatitis caused by Bacillus Calmette-Guerin (BCG) infection after BCG bladder instillation.

Authors:  F W Leebeek; R J Ouwendijk; A H Kolk; A Dees; J C Meek; J E Nienhuis; A M Dingemans-Dumas
Journal:  Gut       Date:  1996-04       Impact factor: 23.059

Review 6.  Current recommendations for the management of bladder cancer. Drug therapy.

Authors:  J A Witjes
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

7.  Effects of sequential intravesical administration of mitomycin C and bacillus Calmette-Guérin on the immune response in the guinea pig bladder.

Authors:  L T Balemans; P D Vegt; P A Steerenberg; E C De Boer; A Van Swaaij; R E De Vries; A P Van der Meijden; W Den Otter
Journal:  Urol Res       Date:  1994

8.  [Sepsis and multiple organ failure after BCG-instillation for bladder cancer].

Authors:  A Elmer; U Bermes; L Drath; E Büscher; A Viertel
Journal:  Internist (Berl)       Date:  2004-08       Impact factor: 0.743
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.